预约演示
更新于：2026-02-08
Norethindrone/Ethinyl Estradiol
醋酸炔诺酮/炔雌醇
更新于：2026-02-08
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H52O5 |
InChIKeyGEONECATAKDDLT-JDSZYESASA-N |
CAS号8015-12-1 |
关联
31
项与 醋酸炔诺酮/炔雌醇 相关的临床试验NCT07074327
Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects
NCT06310616
A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics of Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol (Loestrin) When Co-administered With VH4524184 in Healthy Adult Female Participants
NCT05891262
A Phase 1, Single-center, Open-label, Single-sequence Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 With Oral Contraceptives in Healthy Female Participants
100 项与 醋酸炔诺酮/炔雌醇 相关的临床结果
登录后查看更多信息
100 项与 醋酸炔诺酮/炔雌醇 相关的转化医学
登录后查看更多信息
100 项与 醋酸炔诺酮/炔雌醇 相关的专利（医药）
登录后查看更多信息
204
项与 醋酸炔诺酮/炔雌醇 相关的文献（医药）2025-02-23Cureus Journal of Medical Science
Implications of Non-compliance in the Management of Chronic Polycystic Ovarian Syndrome
Article
作者: Willette, Avarie ; Nicely, Taylor ; Cazes, Elliot
Polycystic ovarian syndrome (PCOS) is a reproductive endocrine disorder characterized by an imbalanced luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratio, which can lead to a range of complications, including infertility, metabolic disturbances, and cardiovascular disease. Diagnosis is based on the Rotterdam criteria, which require the presence of at least two of three features: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries. This case study follows a patient, from ages 28 to 34, who presents with complications while managing her PCOS. Diagnostic tests first confirmed excess androgen production and oligo-amenorrhea, leading to the initiation of metformin hydrochloride (HCl) and Lo Loestrin Fe, a low-estrogen oral contraceptive. However, the patient failed to comply with her medication regimen. Four years later, the patient returned with ongoing irregular bleeding episodes and severe hirsutism. This case addresses the importance of understanding medication non-compliance in the management of chronic conditions such as PCOS, where factors such as financial hardship and lack of understanding about the condition can hinder treatment adherence. Improved patient education, proactive management of medication side effects, and assistance with healthcare costs are essential to improving adherence and long-term health outcomes.
2024-11-01AACE clinical case reports
Endocrine Care of a 19-year-old Woman With Isolated Hypogonadotropic Hypogonadism due to 4H Syndrome
Article
作者: Basnet, Prava ; Odukudu, God-Dowell O ; Kundu, Sumana ; Nwatamole, Bright ; Mirza, Lubna
Background/Objective:
4H syndrome is a rare form of leukodystrophy characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. In 95% of cases, hypomyelination is present, but other clinical features, such as hypodontia and hypogonadotropic hypogonadism, are not always present and may not be necessary for diagnosis. Hypogonadotropic hypogonadism is the most common endocrine complication that can occur in 4H syndrome. Other endocrine abnormalities are short stature and growth hormone deficiency.
Case Report:
We present a 19-year-old female with 4H syndrome due to POLR3B gene mutations who presented with primary amenorrhea. She was referred to our endocrinology clinic by her primary care physician. She was diagnosed with 4H syndrome at age 15 by her pediatrician when she initially presented with primary amenorrhea, ataxia, and tremors and underwent karyotyping and confirmatory genetic tests. However, she received no endocrine care before coming to our clinic at 19. Neurologic exam revealed slight tremors in outstretched hands. A brain MRI study revealed no intracranial abnormalities. We subsequently placed her on Loestrin birth control, an estrogen/progestin combination contraceptive, and she begun having her menstrual periods.
Discussion:
The prevalence of POLR3-related leukodystrophy is currently unknown. It can appear during childhood or later in life. Early onset increases the risk of mortality in young adulthood. Endocrine care entails hormone replacement therapy and monitoring for dysfunction over time.
Conclusion:
Early diagnosis of hypogonadotropic hypogonadism in women, with or without other hormonal deficiencies caused by 4H syndrome, is crucial for effective treatment. Treatment should be multidisciplinary and aimed mainly at correcting low estrogen levels.
2021-09-01Post reproductive health
Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma
Article
作者: Persic, M ; Richardson, A ; Watson, L ; Phillips, A
Objectives:
Studies investigating the safety of hormone replacement therapy in cervical cancer have predominantly included patients with squamous disease. Pathological studies have identified estrogen receptor positivity in cervical adenocarcinomas. A recent small case-control study suggested a trend towards reduced survival with hormone replacement therapy in cervical adenocarcinomas. Our objective was to determine if hormone replacement therapy use in patients treated for cervical adenocarcinomas is detrimental to survival.
Study design:
A retrospective review of all women under the age of 50 with stage 1B-2B cervical adenocarcinomas diagnosed between 1 November 2000 and 24 September 2019. Women were categorised into three groups: ovaries conserved (OVCON); or iatrogenic menopause with (IM-HRT) or without (IM-NOHRT) hormone replacement therapy. Hormone replacement therapy use was defined on an intention to treat basis. Statistical analysis was performed using Kaplan-Meier and Cox proportional hazards methods.
Main outcome measures:
Overall (OS), disease specific (DSS) and progression free (PFS) survival.
Results:
A total of 58 women (mean age 38.5 ± 6.6) were included in the study of whom 25 (43.1%) had OVCON, 20 (34.4%) had IM-HRT and 13 (22.4%) had IM-NOHRT. No menopause-associated deaths occurred. Although five-year DSS was 73% in IM-NOHRT compared to 95% in IM-HRT and 95% in OVCON, these differences were not statistically significant. Five-year PFS was 68% in IM-NOHRT compared to 90% in IM-HRT and 81% in OVCON but again, these differences were not statistically significant.
Conclusion:
In this small study, hormone replacement therapy does not appear to be detrimental to survival in cervical adenocarcinomas. There is a trend towards improved survival with hormone replacement therapy. Larger studies are required to substantiate these findings.
100 项与 醋酸炔诺酮/炔雌醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 代谢性骨病 | 美国 | 1999-10-15 | |
| 骨质吸收 | 美国 | 1999-10-15 | |
| 绝经期后骨质疏松 | 美国 | 1999-10-15 | |
| 血管舒缩症 | 美国 | 1999-10-15 | |
| 血管舒缩症 | 美国 | 1999-10-15 | |
| 避孕 | 美国 | 1973-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
FDA_CDER 人工标引  | N/A | 743 | 鹽艱積蓋窪遞廠艱鹹壓(構積壓鹽齋壓憲鬱鹹蓋) = headache (6.3%), vaginal candidiasis (6.1%), nausea (4.6%), menstrual cramps (4.4%), breast tenderness (3.4%), bacterial vaginitis (3.1%), abnormal cervical smear (3.1%), acne (2.7%), mood swings (2.2%), and weight gain (2.0%). 繭獵鬱憲餘廠積選醖齋 (艱範餘構範鏇選構顧積 ) | 积极 | 2024-07-22 | ||
N/A | 33 | (Ortho-Novum® 1/35) | 觸範繭憲鹹糧壓築顧鹹(構餘廠齋壓壓範遞夢鏇) = 鬱繭獵築襯鬱憲觸築艱 範齋繭積鑰鏇淵憲顧蓋 (夢壓遞構選憲窪醖繭範, 願鹹襯觸憲獵顧遞鹹簾 ~ 醖獵艱顧鏇糧鑰憲築願) 更多 | - | 2018-02-23 | ||
(Ovcon Fe®) | 觸範繭憲鹹糧壓築顧鹹(構餘廠齋壓壓範遞夢鏇) = 夢積顧構繭積觸糧淵觸 範齋繭積鑰鏇淵憲顧蓋 (夢壓遞構選憲窪醖繭範, 鏇鹽鬱廠繭糧積選觸範 ~ 鬱願窪繭壓構齋範遞製) 更多 | ||||||
临床2期 | 217 | (Lifestyle Intervention) | 鏇構製鑰製淵糧簾窪蓋 = 衊鑰窪網壓顧膚襯鑰淵 積顧餘壓壓壓選獵夢顧 (蓋壓鑰繭鹽衊範鹽夢鏇, 選醖襯糧簾築選選鹹淵 ~ 淵觸網遞憲膚鹽鹹繭夢) 更多 | - | 2015-12-17 | ||
(Oral Contraceptives (OCP)) | 鏇構製鑰製淵糧簾窪蓋 = 廠糧憲齋襯鑰願夢繭構 積顧餘壓壓壓選獵夢顧 (蓋壓鑰繭鹽衊範鹽夢鏇, 鑰積製選遞廠壓壓淵衊 ~ 鑰選糧鏇壓製襯築選夢) 更多 | ||||||
临床1期 | - | 36 | Ethinyl Estradiol+Norethindrone (Norethindrone/Ethinyl Estradiol (Test)) | 網膚獵構鑰顧獵遞選繭(艱艱壓顧餘鹽衊憲淵膚) = 廠蓋夢廠淵廠網積餘鏇 鬱蓋觸襯範網壓築鏇顧 (膚遞鬱夢壓繭網衊構獵, 1.7393) 更多 | - | 2011-05-30 | |
Fe (FEMCON® Fe (Reference)) | 網膚獵構鑰顧獵遞選繭(艱艱壓顧餘鹽衊憲淵膚) = 築遞夢鹹艱選齋蓋範膚 鬱蓋觸襯範網壓築鏇顧 (膚遞鬱夢壓繭網衊構獵, 1.6696) 更多 | ||||||
临床1期 | - | 36 | Ethinyl Estradiol+Norethindrone (Norethindrone/Ethinyl Estradiol (Test)) | 鹹衊齋範憲憲遞製壓衊(蓋築夢獵網積構繭淵鑰) = 願鑰壓淵糧艱膚淵製鏇 構醖齋餘製膚膚願願艱 (鹽獵淵壓窪窪構觸鹽憲, 5.22) 更多 | - | 2011-05-25 | |
(Ovcon® 35 Fe (Reference)) | 鹹衊齋範憲憲遞製壓衊(蓋築夢獵網積構繭淵鑰) = 簾鹽壓淵憲鏇壓艱鏇衊 構醖齋餘製膚膚願願艱 (鹽獵淵壓窪窪構觸鹽憲, 4.13) 更多 | ||||||
临床3期 | 1,700 | Ethinyl Estradiol+Norethindrone | 夢憲鑰範淵鹽積構膚獵 = 壓窪範範壓襯鏇壓顧鏇 遞繭鹽艱鏇願膚製醖繭 (顧鹹積夢壓簾蓋選齋廠, 鹽範憲製窪鑰獵夢鏇夢 ~ 膚範壓鑰糧鏇糧襯窪築) 更多 | - | 2011-01-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用